Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Commentary|Articles|June 23, 2026
ADA 2026: Obesity Pharmacotherapy and the Future of Weight Management
Fact checked by: Gillian McGovern, Editor
Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.
Advertisement
Advertisement
If there was one therapeutic area that generated excitement throughout the 86th American Diabetes Association (ADA) Scientific Sessions, it was obesity pharmacotherapy. While glucagon-like peptide (GLP)-1 receptor agonists transformed obesity treatment over the past several years, ADA 2026 provided a glimpse into what may come next: triple agonists, amylin analogues, dual GLP-1/glucagon therapies, and next-generation combination approaches capable of producing unprecedented weight loss while improving glycemic control and cardiometabolic health.
Related to this article
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
Advertisement
Advertisement